Market expansion Astellas is expanding offices into China and Ireland, signaling a strategic push into Asia and Europe. This creates opportunities for localized supply chain optimization, regulatory support services, and partnership opportunities with regional distributors and contract manufacturers.

Competitive landscape With Eli Lilly challenging Padcev in bladder cancer and broader competition in oncology, there is a clear need for strategic collaborations, licensing discussions, and value-driven partnerships to strengthen Astellas’ portfolio against peers.

R&D focus Astellas emphasizes transformative therapies across oncology, ophthalmology, urology, immunology, and women's health. This presents cross-division sales opportunities for research tools, clinical trial services, manufacturing scalability, and companion diagnostics.

Leadership changes Recent leadership turnover in the strategy office indicates potential shifts in strategic priorities. This may open avenues for executive-level engagements, strategic planning support, and collaboration on long-term growth initiatives.

Sustainability & tech Adherence to ISO 14001 and reliance on cloud and enterprise systems suggests opportunities to offer sustainability reporting tooling, ESG data services, and IT/operational optimization to support compliant, efficient global operations.